A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

Inclusion Criteria:

- Have type 2 diabetes mellitus (based on the World Health Organization's [WHO]
diagnostic criteria)

- Have been treated with an SGLT2 inhibitor, with or without metformin, for at least 3
months prior to study entry (minimum required doses for that period for allowed SGLT2
inhibitors: empagliflozin 10 mg, dapagliflozin 5 or 10 mg [per country-specific
label], canagliflozin 100 mg); minimum required dose for metformin, if used, is ≥1500
mg/day and must be reached (or highest tolerated dose which is acceptable with
documented gastrointestinal [GI] intolerability)

- Daily doses of all allowed oral antihyperglycemia agent (OAMs) must have been stable
for at least 12 weeks (±3 days) prior to randomization (study enrollment); daily doses
of SGLT2 inhibitor and metformin, if used, will be considered stable during this
period if:

- all prescribed daily doses were in the range between the minimum required dose
and maximum-approved dose per country-specific label; and

- >90% of prescribed daily doses were equal to the dose at randomization

- Have HbA1c ≥7.0% and ≤9.5% at study entry and approximately 1 week prior to
randomization

- Have body mass index (BMI) ≤45 kilograms per meter squared (kg/m^2) and agree to not
initiate a diet and/or exercise program during the study with the intent of reducing
body weight other than the lifestyle and dietary measures for diabetes treatment

Exclusion Criteria:

- Have type 1 diabetes mellitus

- Have been treated with any other OAMs (other than SGLT2 inhibitors and metformin),
glucagon-like peptide-1 receptor agonist (GLP-1 RA), pramlintide or insulin 3 months
prior to study entry, or between study entry and randomization; or initiate metformin
between study entry and randomization; short-term use of insulin for acute care (≤14
days) during the 3-month period prior to entry is not exclusionary

- Have any condition that is a contraindication for use of the GLP-1 RA class or the
SGLT2 inhibitor class (per country-specific labels) at study entry or develop such
condition between study entry and randomization

- Have acute or chronic hepatitis, signs and symptoms of any other liver disease other
than nonalcoholic fatty liver disease (NAFLD), or alanine transaminase (ALT) level
>2.5 times the upper limit of the reference range, as determined by the central
laboratory at study entry; participants with NAFLD are eligible for participation in
this trial

- Had chronic or acute pancreatitis any time prior to study entry

- Estimated glomerular filtration rate (eGFR) <45 milliliters(mL)/minute/1.73m^2,
calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation, as
determined by the central laboratory at study entry and confirmed at lead in

- Have any self or family history of type 2A or type 2B multiple endocrine neoplasia
(MEN 2A or 2B) in the absence of known C-cell hyperplasia (this exclusion includes
participants with a family history of MEN 2A or 2B, whose family history for the
syndrome is rearranged during transfect [RET]-negative; the only exception for this
exclusion will be for participants whose family members with MEN 2A or 2B have a known
RET mutation and the potential participant for the study is negative for the RET
mutation)

- Have any self or family history of medullary C-cell hyperplasia, focal hyperplasia,
carcinoma (including sporadic, familial, or part of MEN 2A or 2B syndrome)

- Have a serum calcitonin ≥20 picograms/mL as determined by the central laboratory at
study entry